Dillmann, Johannes and Popp, Felix C. and Fillenberg, Barbara and Zeman, Florian and Eggenhofer, Elke and Farkas, Stefan and Scherer, Marcus N. and Koller, Michael and Geissler, Edward K. and Deans, Robert and Ladenheim, Deborah and Loss, Martin and Schlitt, Hans J. and Dahlke, Marc H. (2012) Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation. TRIALS, 13: 211. ISSN 1745-6215,
Full text not available from this repository. (Request a copy)Abstract
Background: Cellular therapy after organ transplantation is emerging as an intriguing strategy to achieve dose reduction of classical immunosuppressive pharmacotherapy. Here, we introduce a new scoring system to assess treatment-emergent adverse events (TEAEs) of adherent stem cell therapies in the clinical setting of allogeneic liver transplantation (for example, the MiSOT-I trial Eudract CT: 2009-017795-25). Methods: The score consists of three independent modalities (set of parameters) that focus on clinically relevant events early after intravenous or intraportal stem cell infusion: pulmonary toxicity, intraportal-infusional toxicity and systemic toxicity. For each modality, values between 0 (no TEAE) and 3 (severe TEAE) were defined. The score was validated retrospectively on a cohort of n=187 recipients of liver allografts not receiving investigational cell therapy between July 2004 and December 2010. These patients represent a control population for further trials. Score values were calculated for days 1, 4, and 10 after liver transplantation. Results: Grade 3 events were most commonly related to the pulmonary system (3.5% of study cohort on day 4). Almost no systemic-related TEAEs were observed during the study period. The relative frequency of grade 3 events never exceeded 5% over all modalities and time points. A subgroup analysis for grade 3 patients provided no descriptors associated with severe TEAEs. Conclusion: The MiSOT-I score provides an assessment tool to score specific adverse events that may occur after adherent stem cell therapy in the clinical setting of organ transplantation and is thus a helpful tool to conduct a safety study.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ORTHOTOPIC LIVER-TRANSPLANTATION; HEPATIC-ARTERY THROMBOSIS; ADULT PROGENITOR CELLS; VASCULAR COMPLICATIONS; VEIN STENOSIS; RISK-FACTORS; DOPPLER US; THROMBOEMBOLISM; ANAPHYLAXIS; MANAGEMENT; Adherent adult stem cells; Mesenchymal stem cells; Multipotent adult progenitor cells; Solid organ transplantation; Immunotherapy; Scoring adverse events; Phase I trial |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 May 2020 07:13 |
| Last Modified: | 04 May 2020 07:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/17803 |
Actions (login required)
 |
View Item |
